Introduction to AMVUTTRA® (vutrisiran)

amvuttra (vutrisiran) injection 25 mg/0.5 mL

Please join your colleagues for a discussion about AMVUTTRA, sponsored by Alnylam Pharmaceuticals.

This program will

- Discuss a hypothetical patient case, including symptom presentation, diagnosis, and management goals
- Provide an overview of the cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM)
- Review the mechanism of action for AMVUTTRA
- Review the clinical profile of AMVUTTRA for the treatment of ATTR-CM
- Review AMVUTTRA access and support

Presenters

Chris Bell, RN, MSN, ACNP

Cardiology Associates of North Mississippi

and Marty, treated with AMVUTTRA

Date & Time

Tuesday, June 9, 2026 6:30 PM CDT

Location

Perry's Steakhouse & Grille
4 Perimeter Park South Birmingham, AL

Dinner will be provided.
To comply with PhRMA Code guidance, alcohol is not provided at Alnylam programs.

REGISTER NOW!

Sign up at:https://alnylamevents.com/hcpevents?id=EM-05811 or call 1-833-223-2204

For questions, please contact:
David Bostick at **dbostick@alnylam.com and/or (205) 305-1238**

This program is intended for US healthcare professionals only. Guests and spouses may not attend this program. Additionally, any meals offered in connection with this program may be reportable and publicly disclosed as required by the Physician Payments Sunshine Act and any applicable state laws. US healthcare professionals must provide their NPI and/or State License Number to register for the program. This is not an accredited education program, and no CME credits are offered. Presenters are consultants of Alnylam.

Indication

AMVUTTRA® (vutrisiran) is indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.

Please see Important Safety Information on the next page and the full Prescribing Information.

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

The most common adverse reactions (≥5%) were pain in extremity, arthralgia, dyspnea, and vitamin A decreased.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Alnylam® PHARMACEUTICALS

amvuttra (vutrisiran) injection 25 mg/0.5 mL